Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Codexis, Inc. - Common Stock (NQ:CDXS)

1.675 -0.365 (-17.89%)
Streaming Delayed Price Updated: 12:48 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Codexis, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Codexis Inc (NASDAQ:CDXS) Plummets After Q3 2025 Revenue and Earnings Miss
Codexis stock plunges after Q3 2025 earnings miss estimates, with revenue of $8.6M falling far short of expectations. 
Via Chartmill
Topics Earnings
What's going on in today's after hours session
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Earnings Scheduled For November 6, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
A Look at Codexis's Upcoming Earnings Report
 
Via Benzinga
Preview: Codexis's Earnings
 
Via Benzinga
Codexis Revenue Jumps 91 Percent in Q2
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Codexis Inc (NASDAQ:CDXS) Surpasses Q2 2025 Earnings Expectations with Strong Revenue and EPS Beat
Codexis Inc (CDXS) beat Q2 2025 revenue and EPS estimates, driving a 6.89% after-hours stock surge. Strong enzyme engineering and RNAi therapeutic progress fuel optimism. 
Via Chartmill
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga
Recap: Codexis Q4 Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Earnings Scheduled For August 13, 2025
 
Via Benzinga
Earnings Scheduled For May 14, 2025
 
Via Benzinga
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
CDXS Stock Earnings: Codexis Misses EPS, Beats Revenue for Q2 2024
CDXS stock results show that Codexis missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
CDXS Stock Earnings: Codexis Beats EPS, Beats Revenue for Q1 2024
CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Codexis Clinches Deal With Nestlé Health Science, Eyes Up To $45M Milestone In EPI Treatment Breakthrough
Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).  
Via Benzinga
“Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally”
Via AB Newswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.